IDenta Corp.
IDenta Corp. (IDTA) Stock Competitors & Peer Comparison
See (IDTA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDTA | $0.18 | +0.00% | 708K | 8.75 | $0.02 | N/A |
| LZAGY | $63.19 | -2.89% | 44.8B | 37.94 | $1.66 | +0.68% |
| LZAGF | $635.20 | -2.91% | 44.7B | 38.29 | $16.61 | +0.37% |
| WUXAY | $15.60 | +1.68% | 44.6B | 16.08 | $0.97 | +1.17% |
| WUXIF | $13.88 | +0.00% | 41.4B | 14.31 | $0.97 | +1.68% |
| ERFSF | $73.92 | +0.13% | 12.7B | 24.15 | $3.01 | +0.94% |
| BMXMF | $105.41 | +0.00% | 12.4B | 26.75 | $3.94 | +0.98% |
| SKHHY | $14.27 | -0.28% | 7.1B | 18.27 | $0.79 | +5.08% |
| SKHCF | $14.58 | +4.14% | 7.1B | 18.10 | $0.79 | +5.09% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
Stock Comparison
IDTA vs LZAGY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, LZAGY has a market cap of 44.8B. Regarding current trading prices, IDTA is priced at $0.18, while LZAGY trades at $63.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas LZAGY's P/E ratio is 37.94. In terms of profitability, IDTA's ROE is +0.13%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, IDTA is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check LZAGY's competition here
IDTA vs LZAGF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, LZAGF has a market cap of 44.7B. Regarding current trading prices, IDTA is priced at $0.18, while LZAGF trades at $635.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas LZAGF's P/E ratio is 38.29. In terms of profitability, IDTA's ROE is +0.13%, compared to LZAGF's ROE of +0.10%. Regarding short-term risk, IDTA is more volatile compared to LZAGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check LZAGF's competition here
IDTA vs WUXAY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, WUXAY has a market cap of 44.6B. Regarding current trading prices, IDTA is priced at $0.18, while WUXAY trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas WUXAY's P/E ratio is 16.08. In terms of profitability, IDTA's ROE is +0.13%, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, IDTA is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check WUXAY's competition here
IDTA vs WUXIF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, IDTA is priced at $0.18, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas WUXIF's P/E ratio is 14.31. In terms of profitability, IDTA's ROE is +0.13%, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, IDTA is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check WUXIF's competition here
IDTA vs ERFSF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ERFSF has a market cap of 12.7B. Regarding current trading prices, IDTA is priced at $0.18, while ERFSF trades at $73.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ERFSF's P/E ratio is 24.15. In terms of profitability, IDTA's ROE is +0.13%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, IDTA is more volatile compared to ERFSF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ERFSF's competition here
IDTA vs BMXMF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BMXMF has a market cap of 12.4B. Regarding current trading prices, IDTA is priced at $0.18, while BMXMF trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BMXMF's P/E ratio is 26.75. In terms of profitability, IDTA's ROE is +0.13%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, IDTA is more volatile compared to BMXMF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BMXMF's competition here
IDTA vs SKHHY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SKHHY has a market cap of 7.1B. Regarding current trading prices, IDTA is priced at $0.18, while SKHHY trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SKHHY's P/E ratio is 18.27. In terms of profitability, IDTA's ROE is +0.13%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, IDTA is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SKHHY's competition here
IDTA vs SKHCF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SKHCF has a market cap of 7.1B. Regarding current trading prices, IDTA is priced at $0.18, while SKHCF trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SKHCF's P/E ratio is 18.10. In terms of profitability, IDTA's ROE is +0.13%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, IDTA is more volatile compared to SKHCF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SKHCF's competition here
IDTA vs HNGZY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, IDTA is priced at $0.18, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, IDTA's ROE is +0.13%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, IDTA is more volatile compared to HNGZY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check HNGZY's competition here
IDTA vs DSRLF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, DSRLF has a market cap of 3.9B. Regarding current trading prices, IDTA is priced at $0.18, while DSRLF trades at $71.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas DSRLF's P/E ratio is 21.47. In terms of profitability, IDTA's ROE is +0.13%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, IDTA is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check DSRLF's competition here
IDTA vs VIMGF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, IDTA is priced at $0.18, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, IDTA's ROE is +0.13%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, IDTA is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check VIMGF's competition here
IDTA vs GNTLF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, IDTA is priced at $0.18, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, IDTA's ROE is +0.13%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, IDTA is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check GNTLF's competition here
IDTA vs MRCHF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, IDTA is priced at $0.18, while MRCHF trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MRCHF's P/E ratio is 44.29. In terms of profitability, IDTA's ROE is +0.13%, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, IDTA is more volatile compared to MRCHF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check MRCHF's competition here
IDTA vs IDGXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, IDTA is priced at $0.18, while IDGXF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IDGXF's P/E ratio is 16.00. In terms of profitability, IDTA's ROE is +0.13%, compared to IDGXF's ROE of +0.28%. Regarding short-term risk, IDTA is more volatile compared to IDGXF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check IDGXF's competition here
IDTA vs EDTXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, EDTXF has a market cap of 297.8M. Regarding current trading prices, IDTA is priced at $0.18, while EDTXF trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas EDTXF's P/E ratio is -8.46. In terms of profitability, IDTA's ROE is +0.13%, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, IDTA is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check EDTXF's competition here
IDTA vs AMCY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, IDTA is priced at $0.18, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas AMCY's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to AMCY's ROE of N/A. Regarding short-term risk, IDTA is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check AMCY's competition here
IDTA vs NNGRF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, IDTA is priced at $0.18, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, IDTA's ROE is +0.13%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, IDTA is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check NNGRF's competition here
IDTA vs DIUXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, IDTA is priced at $0.18, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, IDTA's ROE is +0.13%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, IDTA is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check DIUXF's competition here
IDTA vs CORBF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, CORBF has a market cap of 127.3M. Regarding current trading prices, IDTA is priced at $0.18, while CORBF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas CORBF's P/E ratio is 2.72. In terms of profitability, IDTA's ROE is +0.13%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, IDTA is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check CORBF's competition here
IDTA vs LDXHF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, LDXHF has a market cap of 99.2M. Regarding current trading prices, IDTA is priced at $0.18, while LDXHF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas LDXHF's P/E ratio is -13.00. In terms of profitability, IDTA's ROE is +0.13%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, IDTA is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check LDXHF's competition here
IDTA vs THOXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, IDTA is priced at $0.18, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas THOXF's P/E ratio is -7.45. In terms of profitability, IDTA's ROE is +0.13%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, IDTA is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check THOXF's competition here
IDTA vs TIHE Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, IDTA is priced at $0.18, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas TIHE's P/E ratio is 0.32. In terms of profitability, IDTA's ROE is +0.13%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, IDTA is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check TIHE's competition here
IDTA vs PFGTF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, IDTA is priced at $0.18, while PFGTF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, IDTA's ROE is +0.13%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, IDTA is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check PFGTF's competition here
IDTA vs BIOGF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, IDTA is priced at $0.18, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, IDTA's ROE is +0.13%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, IDTA is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BIOGF's competition here
IDTA vs PCNEF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, IDTA is priced at $0.18, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, IDTA's ROE is +0.13%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, IDTA is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check PCNEF's competition here
IDTA vs BMKDF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BMKDF has a market cap of 44.5M. Regarding current trading prices, IDTA is priced at $0.18, while BMKDF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BMKDF's P/E ratio is -42.38. In terms of profitability, IDTA's ROE is +0.13%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, IDTA is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BMKDF's competition here
IDTA vs BIOQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, IDTA is priced at $0.18, while BIOQ trades at $37.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, IDTA's ROE is +0.13%, compared to BIOQ's ROE of -0.03%. Regarding short-term risk, IDTA is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BIOQ's competition here
IDTA vs SNANF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SNANF has a market cap of 25.3M. Regarding current trading prices, IDTA is priced at $0.18, while SNANF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SNANF's P/E ratio is -11.07. In terms of profitability, IDTA's ROE is +0.13%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, IDTA is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SNANF's competition here
IDTA vs ANPCY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, IDTA is priced at $0.18, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, IDTA's ROE is +0.13%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, IDTA is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ANPCY's competition here
IDTA vs PCHM Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, IDTA is priced at $0.18, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas PCHM's P/E ratio is -0.02. In terms of profitability, IDTA's ROE is +0.13%, compared to PCHM's ROE of +0.25%. Regarding short-term risk, IDTA is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check PCHM's competition here
IDTA vs VILGF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, IDTA is priced at $0.18, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas VILGF's P/E ratio is -0.30. In terms of profitability, IDTA's ROE is +0.13%, compared to VILGF's ROE of N/A. Regarding short-term risk, IDTA is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check VILGF's competition here
IDTA vs CLIFF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, IDTA is priced at $0.18, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, IDTA's ROE is +0.13%, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, IDTA is more volatile compared to CLIFF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check CLIFF's competition here
IDTA vs LDDD Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, IDTA is priced at $0.18, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas LDDD's P/E ratio is -51.00. In terms of profitability, IDTA's ROE is +0.13%, compared to LDDD's ROE of -0.28%. Regarding short-term risk, IDTA is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check LDDD's competition here
IDTA vs IZOZF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IZOZF has a market cap of 13.9M. Regarding current trading prices, IDTA is priced at $0.18, while IZOZF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IZOZF's P/E ratio is -10.10. In terms of profitability, IDTA's ROE is +0.13%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, IDTA is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check IZOZF's competition here
IDTA vs ABDXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, IDTA is priced at $0.18, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, IDTA's ROE is +0.13%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, IDTA is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ABDXF's competition here
IDTA vs IDXG Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IDXG has a market cap of 8.9M. Regarding current trading prices, IDTA is priced at $0.18, while IDXG trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IDXG's P/E ratio is 2.25. In terms of profitability, IDTA's ROE is +0.13%, compared to IDXG's ROE of +4.85%. Regarding short-term risk, IDTA is more volatile compared to IDXG. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check IDXG's competition here
IDTA vs MXDHF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, IDTA is priced at $0.18, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, IDTA's ROE is +0.13%, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, IDTA is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check MXDHF's competition here
IDTA vs JMPHF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, IDTA is priced at $0.18, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, IDTA's ROE is +0.13%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, IDTA is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check JMPHF's competition here
IDTA vs IMMVF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, IDTA is priced at $0.18, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, IDTA's ROE is +0.13%, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, IDTA is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check IMMVF's competition here
IDTA vs AVCRF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, AVCRF has a market cap of 6.1M. Regarding current trading prices, IDTA is priced at $0.18, while AVCRF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas AVCRF's P/E ratio is -6.03. In terms of profitability, IDTA's ROE is +0.13%, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, IDTA is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check AVCRF's competition here
IDTA vs SQIDF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, IDTA is priced at $0.18, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, IDTA's ROE is +0.13%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, IDTA is more volatile compared to SQIDF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SQIDF's competition here
IDTA vs ICBU Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ICBU has a market cap of 5.4M. Regarding current trading prices, IDTA is priced at $0.18, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ICBU's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, IDTA is more volatile compared to ICBU. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ICBU's competition here
IDTA vs PMSNF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, PMSNF has a market cap of 5.2M. Regarding current trading prices, IDTA is priced at $0.18, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, IDTA's ROE is +0.13%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, IDTA is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check PMSNF's competition here
IDTA vs VRCDF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, IDTA is priced at $0.18, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, IDTA's ROE is +0.13%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, IDTA is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check VRCDF's competition here
IDTA vs RNVA Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, IDTA is priced at $0.18, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas RNVA's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, IDTA is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check RNVA's competition here
IDTA vs TDSGF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, TDSGF has a market cap of 3.9M. Regarding current trading prices, IDTA is priced at $0.18, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas TDSGF's P/E ratio is -3.90. In terms of profitability, IDTA's ROE is +0.13%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, IDTA is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check TDSGF's competition here
IDTA vs ANPCF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ANPCF has a market cap of 3.4M. Regarding current trading prices, IDTA is priced at $0.18, while ANPCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ANPCF's P/E ratio is -0.17. In terms of profitability, IDTA's ROE is +0.13%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, IDTA is more volatile compared to ANPCF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ANPCF's competition here
IDTA vs IBXXF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, IDTA is priced at $0.18, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, IDTA's ROE is +0.13%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, IDTA is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check IBXXF's competition here
IDTA vs IVRO Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IVRO has a market cap of 1.8M. Regarding current trading prices, IDTA is priced at $0.18, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IVRO's P/E ratio is -0.80. In terms of profitability, IDTA's ROE is +0.13%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, IDTA is more volatile compared to IVRO. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check IVRO's competition here
IDTA vs CHHL Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, IDTA is priced at $0.18, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas CHHL's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, IDTA is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check CHHL's competition here
IDTA vs SLDX Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, IDTA is priced at $0.18, while SLDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SLDX's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, IDTA is more volatile compared to SLDX. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SLDX's competition here
IDTA vs DIGP Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, IDTA is priced at $0.18, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas DIGP's P/E ratio is -1.04. In terms of profitability, IDTA's ROE is +0.13%, compared to DIGP's ROE of +1.19%. Regarding short-term risk, IDTA is more volatile compared to DIGP. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check DIGP's competition here
IDTA vs EPGNF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, IDTA is priced at $0.18, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, IDTA's ROE is +0.13%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, IDTA is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check EPGNF's competition here
IDTA vs RSHN Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, IDTA is priced at $0.18, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas RSHN's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, IDTA is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check RSHN's competition here
IDTA vs SZLSF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, IDTA is priced at $0.18, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, IDTA's ROE is +0.13%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, IDTA is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check SZLSF's competition here
IDTA vs SCRSF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, IDTA is priced at $0.18, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, IDTA's ROE is +0.13%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, IDTA is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check SCRSF's competition here
IDTA vs NSTM Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, IDTA is priced at $0.18, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas NSTM's P/E ratio is 0.20. In terms of profitability, IDTA's ROE is +0.13%, compared to NSTM's ROE of -0.83%. Regarding short-term risk, IDTA is more volatile compared to NSTM. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check NSTM's competition here
IDTA vs MBGNF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, IDTA is priced at $0.18, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, IDTA's ROE is +0.13%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, IDTA is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check MBGNF's competition here
IDTA vs NVTAQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, IDTA is priced at $0.18, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, IDTA's ROE is +0.13%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, IDTA is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check NVTAQ's competition here
IDTA vs ARYC Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, IDTA is priced at $0.18, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ARYC's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, IDTA is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check ARYC's competition here
IDTA vs HCLC Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, IDTA is priced at $0.18, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas HCLC's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, IDTA is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check HCLC's competition here
IDTA vs MEDD Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, IDTA is priced at $0.18, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MEDD's P/E ratio is -0.02. In terms of profitability, IDTA's ROE is +0.13%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, IDTA is less volatile compared to MEDD. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check MEDD's competition here
IDTA vs IHTI Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, IDTA is priced at $0.18, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas IHTI's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, IDTA is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check IHTI's competition here
IDTA vs TOMDF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, IDTA is priced at $0.18, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas TOMDF's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, IDTA is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check TOMDF's competition here
IDTA vs CGNH Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, IDTA is priced at $0.18, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas CGNH's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, IDTA is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check CGNH's competition here
IDTA vs ABMC Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, IDTA is priced at $0.18, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ABMC's P/E ratio is 0.01. In terms of profitability, IDTA's ROE is +0.13%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, IDTA is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ABMC's competition here
IDTA vs CYPS Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, IDTA is priced at $0.18, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas CYPS's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to CYPS's ROE of N/A. Regarding short-term risk, IDTA is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check CYPS's competition here
IDTA vs RGDXQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, IDTA is priced at $0.18, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, IDTA is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check RGDXQ's competition here
IDTA vs DMTKQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, IDTA is priced at $0.18, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, IDTA's ROE is +0.13%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, IDTA is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check DMTKQ's competition here
IDTA vs MEDVF Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, IDTA is priced at $0.18, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MEDVF's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, IDTA is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check MEDVF's competition here
IDTA vs GWHP Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, IDTA is priced at $0.18, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas GWHP's P/E ratio is -0.00. In terms of profitability, IDTA's ROE is +0.13%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, IDTA is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check GWHP's competition here
IDTA vs ROSGQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, IDTA is priced at $0.18, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, IDTA is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check ROSGQ's competition here
IDTA vs BIOCQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, IDTA is priced at $0.18, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, IDTA is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BIOCQ's competition here
IDTA vs HTGMQ Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, IDTA is priced at $0.18, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, IDTA is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check HTGMQ's competition here
IDTA vs OPGX Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, OPGX has a market cap of 17. Regarding current trading prices, IDTA is priced at $0.18, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas OPGX's P/E ratio is -0.00. In terms of profitability, IDTA's ROE is +0.13%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, IDTA is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDTA.Check OPGX's competition here
IDTA vs AGHC Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, AGHC has a market cap of 0. Regarding current trading prices, IDTA is priced at $0.18, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas AGHC's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, IDTA is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check AGHC's competition here
IDTA vs EPGNY Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, IDTA is priced at $0.18, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, IDTA's ROE is +0.13%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, IDTA is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check EPGNY's competition here
IDTA vs MRPS Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, MRPS has a market cap of 0. Regarding current trading prices, IDTA is priced at $0.18, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas MRPS's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to MRPS's ROE of N/A. Regarding short-term risk, IDTA is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check MRPS's competition here
IDTA vs BGNX Comparison April 2026
IDTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDTA stands at 708K. In comparison, BGNX has a market cap of 0. Regarding current trading prices, IDTA is priced at $0.18, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDTA currently has a P/E ratio of 8.75, whereas BGNX's P/E ratio is N/A. In terms of profitability, IDTA's ROE is +0.13%, compared to BGNX's ROE of N/A. Regarding short-term risk, IDTA is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for IDTA.Check BGNX's competition here